128 related articles for article (PubMed ID: 14711197)
1. Improvement of ventricular arrhythmia by octreotide treatment in acromegalic cardiomyopathy.
Tachibana H; Yamaguchi H; Abe S; Sato T; Inoue S; Abe S; Yamaki M; Kubota I
Jpn Heart J; 2003 Nov; 44(6):1027-31. PubMed ID: 14711197
[TBL] [Abstract][Full Text] [Related]
2. Octreotide improved ventricular arrhythmia in an acromegalic patient.
Suyama K; Uchida D; Tanaka T; Saito J; Noguchi Y; Nakamura S; Tatsuno I; Saito Y; Saeki N
Endocr J; 2000 Mar; 47 Suppl():S73-5. PubMed ID: 10890189
[TBL] [Abstract][Full Text] [Related]
3. [Acromegalic cardiomyopathy].
Bencze A; Rácz K
Orv Hetil; 2011 Nov; 152(47):1875-8. PubMed ID: 22042313
[TBL] [Abstract][Full Text] [Related]
4. Improvement of intrinsic myocardial contractility and cardiac fibrosis degree in acromegalic patients treated with somatostatin analogues: a prospective study.
Bogazzi F; Di Bello V; Palagi C; Donne MG; Di Cori A; Gavioli S; Talini E; Cosci C; Sardella C; Brogioni S; Mariani M; Martino E
Clin Endocrinol (Oxf); 2005 May; 62(5):590-6. PubMed ID: 15853830
[TBL] [Abstract][Full Text] [Related]
5. Normalisation of plasma growth hormone levels improved cardiac dysfunction due to acromegalic cardiomyopathy with severe fibrosis.
Yokota F; Arima H; Hirano M; Uchikawa T; Inden Y; Nagatani T; Oiso Y
BMJ Case Rep; 2010 Sep; 2010():. PubMed ID: 22791498
[TBL] [Abstract][Full Text] [Related]
6. Improvement of cardiac function after treatment with octreotide followed by trans-sphenoidal surgery in an acromegalic patient who presented with congestive heart failure.
Shimakura A; Miyakoshi H; Ohkuwa H; Kitabayashi M; Komai T; Hisada A; Aoki K; Sakagami S; Kobayashi K; Takata S
Jpn Heart J; 2002 Jan; 43(1):69-77. PubMed ID: 12041892
[TBL] [Abstract][Full Text] [Related]
7. Cardiovascular effects of depot long-acting somatostatin analog Sandostatin LAR in acromegaly.
Colao A; Marzullo P; Ferone D; Spinelli L; Cuocolo A; Bonaduce D; Salvatore M; Boerlin V; Lancranjan I; Lombardi G
J Clin Endocrinol Metab; 2000 Sep; 85(9):3132-40. PubMed ID: 10999798
[TBL] [Abstract][Full Text] [Related]
8. Is the acromegalic cardiomyopathy reversible? Effect of 5-year normalization of growth hormone and insulin-like growth factor I levels on cardiac performance.
Colao A; Cuocolo A; Marzullo P; Nicolai E; Ferone D; Della Morte AM; Pivonello R; Salvatore M; Lombardi G
J Clin Endocrinol Metab; 2001 Apr; 86(4):1551-7. PubMed ID: 11297582
[TBL] [Abstract][Full Text] [Related]
9. [Experience in treating acromegalic patients with long-acting octreotide].
Szücs N; Mészáros J; Czirják S; Mondok A; Varga I; Gláz E
Orv Hetil; 2002 May; 143(19 Suppl):1066-70. PubMed ID: 12063862
[TBL] [Abstract][Full Text] [Related]
10. Effects of initial therapy for five years with somatostatin analogs for acromegaly on growth hormone and insulin-like growth factor-I levels, tumor shrinkage, and cardiovascular disease: a prospective study.
Colao A; Auriemma RS; Galdiero M; Lombardi G; Pivonello R
J Clin Endocrinol Metab; 2009 Oct; 94(10):3746-56. PubMed ID: 19622615
[TBL] [Abstract][Full Text] [Related]
11. [Current alternative in the pharmacotherapy of acromegaly: the long-acting somatostatin analogue octreotide].
Laczi F; Magony S; Julesz J
Orv Hetil; 2002 May; 143(19 Suppl):1062-6. PubMed ID: 12063861
[TBL] [Abstract][Full Text] [Related]
12. [Outcome of somatostatin analogue treatment in acromegaly].
Mondok A; Tóth M; Patócs A; Szücs N; Igaz P; Pusztai P; Czirják S; Beko G; Gláz E; Rácz K; Tulassay Z
Orv Hetil; 2009 Aug; 150(31):1457-62. PubMed ID: 19617182
[TBL] [Abstract][Full Text] [Related]
13. [Novel pharmacologic therapies in acromegaly].
Góth M; Hubina E; Kovács L; Szabolcs I
Orv Hetil; 2002 May; 143(19 Suppl):1057-62. PubMed ID: 12063860
[TBL] [Abstract][Full Text] [Related]
14. Effects of 1-year treatment with octreotide on cardiac performance in patients with acromegaly.
Colao A; Cuocolo A; Marzullo P; Nicolai E; Ferone D; Florimonte L; Salvatore M; Lombardi G
J Clin Endocrinol Metab; 1999 Jan; 84(1):17-23. PubMed ID: 9920056
[TBL] [Abstract][Full Text] [Related]
15. Cardiovascular consequences of early-onset growth hormone excess.
Colao A; Spinelli L; Cuocolo A; Spiezia S; Pivonello R; di Somma C; Bonaduce D; Salvatore M; Lombardi G
J Clin Endocrinol Metab; 2002 Jul; 87(7):3097-104. PubMed ID: 12107207
[TBL] [Abstract][Full Text] [Related]
16. Medical treatment of acromegaly: comorbidities and their reversibility by somatostatin analogs.
Tolis G; Angelopoulos NG; Katounda E; Rombopoulos G; Kaltzidou V; Kaltsas D; Protonotariou A; Lytras A
Neuroendocrinology; 2006; 83(3-4):249-57. PubMed ID: 17047390
[TBL] [Abstract][Full Text] [Related]
17. Reversible shrinkage of a growth hormone-secreting pituitary adenoma by a long-acting somatostatin analogue, octreotide.
Barakat S; Melmed S
Arch Intern Med; 1989 Jun; 149(6):1443-5. PubMed ID: 2730266
[TBL] [Abstract][Full Text] [Related]
18. A case and review of acromegaly-induced cardiomyopathy and the relationship between growth hormone and heart failure: cause or cure or neither or both?
Schwarz ER; Jammula P; Gupta R; Rosanio S
J Cardiovasc Pharmacol Ther; 2006 Dec; 11(4):232-44. PubMed ID: 17220469
[TBL] [Abstract][Full Text] [Related]
19. Control of tumor size and disease activity during cotreatment with octreotide and the growth hormone receptor antagonist pegvisomant in an acromegalic patient.
van der Lely AJ; Muller A; Janssen JA; Davis RJ; Zib KA; Scarlett JA; Lamberts SW
J Clin Endocrinol Metab; 2001 Feb; 86(2):478-81. PubMed ID: 11157994
[TBL] [Abstract][Full Text] [Related]
20. Endoscopic therapy and curative effect in pituitary adenoma patients complicated by acromegalic cardiomyopathy.
Zhou H; Zha Z; Li X; Chen X; Wang J; Su Z
Neurosurg Rev; 2018 Jul; 41(3):869-875. PubMed ID: 29238923
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
